Laurel Wealth Advisors Inc. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 170.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,018 shares of the medical research company’s stock after purchasing an additional 1,272 shares during the quarter. Laurel Wealth Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $1,111,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Polen Capital Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $1,208,055,000. Ontario Teachers Pension Plan Board bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at about $433,169,000. CIBC Private Wealth Group LLC lifted its holdings in Thermo Fisher Scientific by 107.5% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,391,587 shares of the medical research company’s stock valued at $759,715,000 after buying an additional 720,823 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at about $209,946,000. Finally, Vanguard Group Inc. lifted its holdings in Thermo Fisher Scientific by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 32,166,910 shares of the medical research company’s stock valued at $16,314,735,000 after buying an additional 406,844 shares in the last quarter. 85.92% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on TMO shares. KeyCorp decreased their price objective on shares of Thermo Fisher Scientific from $710.00 to $640.00 in a report on Thursday, May 25th. Barclays reduced their price target on shares of Thermo Fisher Scientific from $625.00 to $610.00 in a report on Thursday, April 27th. StockNews.com assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, May 18th. They issued a “hold” rating for the company. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $693.00 to $670.00 in a report on Thursday, April 27th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 in a research report on Thursday, May 25th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $631.31.
Thermo Fisher Scientific Stock Up 1.1 %
TMO stock opened at $523.69 on Tuesday. The firm’s fifty day simple moving average is $543.64 and its 200-day simple moving average is $554.34. The company has a market capitalization of $202.00 billion, a P/E ratio of 34.14, a price-to-earnings-growth ratio of 2.57 and a beta of 0.79. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.27 and a quick ratio of 0.92. Thermo Fisher Scientific Inc. has a 12 month low of $475.77 and a 12 month high of $611.06.
Thermo Fisher Scientific (NYSE:TMO – Get Rating) last posted its earnings results on Wednesday, April 26th. The medical research company reported $5.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $5.03. Thermo Fisher Scientific had a net margin of 13.75% and a return on equity of 19.16%. The firm had revenue of $10.71 billion during the quarter, compared to analysts’ expectations of $10.67 billion. During the same period in the previous year, the business posted $7.25 EPS. The business’s revenue was down 9.4% compared to the same quarter last year. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.69 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, July 14th. Investors of record on Thursday, June 15th will be paid a $0.35 dividend. This represents a $1.40 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend is Wednesday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.13%.
Insider Activity at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $545.22, for a total transaction of $5,452,200.00. Following the completion of the transaction, the chief executive officer now directly owns 141,330 shares in the company, valued at $77,055,942.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 1,600 shares of the company’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $534.82, for a total transaction of $855,712.00. Following the completion of the transaction, the chief executive officer now directly owns 141,330 shares in the company, valued at $75,586,110.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Friday, May 5th. The stock was sold at an average price of $545.22, for a total transaction of $5,452,200.00. Following the transaction, the chief executive officer now owns 141,330 shares of the company’s stock, valued at $77,055,942.60. The disclosure for this sale can be found here. Company insiders own 0.32% of the company’s stock.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating).
Receive News & Ratings for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.